What is he best known for?
The fields of study he is best known for:
His primary areas of investigation include Myeloid leukemia, Leukemia, Cancer research, Genetics and Molecular biology.
The Midostaurin research Stefan K. Bohlander does as part of his general Myeloid leukemia study is frequently linked to other disciplines of science, such as Autophosphorylation, therefore creating a link between diverse domains of science.
His studies deal with areas such as Myeloid, RUNX1 Translocation Partner 1 Protein, Fms-Like Tyrosine Kinase 3 and Stem cell as well as Leukemia.
His work carried out in the field of Cancer research brings together such families of science as Haematopoiesis, Granulopoiesis, CEBPA, Ccaat-enhancer-binding proteins and K562 cells.
He focuses mostly in the field of Genetics, narrowing it down to topics relating to Osteogenesis imperfecta and, in certain cases, Mutation and Silent mutation.
The concepts of his Molecular biology study are interwoven with issues in Chromosomal translocation, ABL, Fluorescence in situ hybridization, Molecular cloning and Multiplex ligation-dependent probe amplification.
His most cited work include:
- Stem cell gene expression programs influence clinical outcome in human leukemia (682 citations)
- Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia (645 citations)
- MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia (421 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Myeloid leukemia, Cancer research, Molecular biology, Leukemia and Genetics.
His Myeloid leukemia research is multidisciplinary, incorporating elements of Stem cell, Oncology and Gene expression profiling.
His Cancer research research integrates issues from Mutation, microRNA, CDX2, RUNX1 and Regulation of gene expression.
The Molecular biology study combines topics in areas such as ETV6, Chromosomal translocation, Fusion gene, Gene cluster and Fluorescence in situ hybridization.
His research in Leukemia tackles topics such as Myeloid which are related to areas like Progenitor cell.
His research integrates issues of Acute lymphocytic leukemia and ABL in his study of Gene.
He most often published in these fields:
- Myeloid leukemia (42.65%)
- Cancer research (35.84%)
- Molecular biology (35.48%)
What were the highlights of his more recent work (between 2015-2021)?
- Myeloid leukemia (42.65%)
- Cancer research (35.84%)
- Leukemia (34.05%)
In recent papers he was focusing on the following fields of study:
Myeloid leukemia, Cancer research, Leukemia, Internal medicine and Myeloid are his primary areas of study.
His Myeloid leukemia research includes elements of Exome sequencing, Proto-Oncogene Proteins, Function and Anti proliferative.
Stefan K. Bohlander has included themes like Tumor hypoxia, Stem cell and Gene, Somatic cell in his Cancer research study.
His Gene study is related to the wider topic of Genetics.
His Leukemia study is concerned with the field of Immunology as a whole.
The various areas that he examines in his Myeloid study include Mutation, CEBPA, Transcriptome, RUNX1 and RUNX1T1.
Between 2015 and 2021, his most popular works were:
- GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo. (84 citations)
- Adults with Philadelphia chromosome–like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis (75 citations)
- miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia (69 citations)
In his most recent research, the most cited papers focused on:
His main research concerns Leukemia, Cancer research, Myeloid leukemia, Myeloid and Internal medicine.
Leukemia is a subfield of Immunology that he tackles.
His research in Cancer research focuses on subjects like Gene, which are connected to Surrogate endpoint.
His Myeloid leukemia study integrates concerns from other disciplines, such as Bioinformatics, Real-time polymerase chain reaction, DNA microarray, Computational biology and Induction chemotherapy.
His research on Myeloid also deals with topics like
- RUNX1T1 which intersects with area such as Lineage, Fusion gene, Molecular biology, MYH11 and Targeted therapy,
- RUNX1 together with Core binding factor,
- Mutation together with Cytarabine.
His studies in Internal medicine integrate themes in fields like CEBPA and Oncology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
